A protocol for pre-treatment testing for antibodies to galactose-alpha-1,3-galactose to mitigate the risk of cetuximab hypersensitivity reactions – a retrospective cohort review

A protocol for pre-treatment testing for antibodies to galactose-alpha-1,3-galactose to mitigate the risk of cetuximab hypersensitivity reactions – a retrospective cohort review

Purpose: Cetuximab improves survival in KRAS wildtype metastatic colorectal cancer. However, high rates of hypersensitivity reactions (HSRs) limit its use, with HSR rates up to 10–20 %. A major driver of cetuximab HSR is from pre-formed IgE antibody response to galactose-1,3-alpha-galactose (alpha-g...

Full description

Saved in:
Bibliographic Details
Main Authors: Nicholas Della Marta, Alexander Yuile, Claire Mok, Joe Wei, Meredith Oatley, Tracey Skinner, Samuel Miller, Amanda L. Hudson, Sheryl van Nunen, Stephen J. Clarke, Connie I. Diakos, Madhawa De Silva, David L. Chan, Gavin M. Marx, Nick Pavlakis
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:Cancer Treatment and Research Communications
Subjects:
Colorectal cancer
Cetuximab
Hypersensitivity reaction
Alpha-gal
Pre-treatment screening
Online Access:http://www.sciencedirect.com/science/article/pii/S2468294225001054
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2468294225001054

Similar Items